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Abstract
Background: When treating bladder cancer patients, the most significant problems usually concern cases with
high-grade non-muscle-invasive carcinoma, and a better understanding of which patients would benefit from early
radical cystectomy is urgently needed. The uropathology community is seeking more user-friendly approaches to
distinguishing between T1 cancers exhibiting different types of clinical behavior.
Methods: After a retrospective review, we selected a group of 314 patients who underwent transurethral resection
of the bladder (TURB) and were diagnosed with high-grade urothelial carcinoma staged as T1. Three different
substaging systems were applied: one was the anatomy-based T1 a/b; and two involved micrometric thresholds of
either 0.5 mm of invasion (as proposed by van Rhijn et al.), or 1 mm of invasion (as proposed in the present study).
Early reTUR (repeated transurethral resection) was performed in 250 patients, and the same substaging approaches
were applied to cases of T1.
Results: It proved feasible to apply the 1 mm substaging system in 100 % of cases, the van Rhijn system in 100 %,
and the anatomy-based method (T1 a/b) in 72.3 % of cases. At a mean follow-up of 46 months, the recurrence-free
survival rate was significantly better (p < 0.001) in the group that underwent reTUR, while none of the three
substaging systems reliably predicted recurrences. The 1 mm did seem promising, however, as a threshold for
predicting progression, reaching statistical significance in the Kaplan Meier estimates (p < 0.04).
Conclusion: Our study shows that micrometric substaging is feasible in this setting and should be extended
to include any early reTUR to complete the substaging done after the first TURB. It can also provide helpful
prognostic information.
Keywords: Urothelial bladder carcinoma, Stage, Substaging system, Prognosis, Progression
Background
Urothelial carcinoma poses a major challenge for Western
health care systems, being the seventh most frequent
cancer and one of the most expensive malignancies to
diagnose and manage [1], making any improvement to
the strategy for diagnosing and treating this disease im-
portant to the medical and scientific community. Non-
muscle-invasive bladder carcinoma (NMIBC) accounts
for about 75 % of bladder cancers, and high-grade T1 is
the subtype of NMIBC at highest risk, with patients
facing long-term cancer-specific mortality rates as high
as 34 % [2]. Due to the impact of this category of pa-
tients, in terms of disease incidence and patient sur-
vival, there are many important clinical and surgical
factors to consider when deciding the best treatment
for T1 bladder carcinoma, that also concern the precise
role of early cystectomy. Issues such as age, gender,
tumor size, number of lesions and time to relapse all
have an important role in the primary treatment of T1
tumors and after first-line BCG treatment has failed
[3]. Pathological factors such as grade [1], histotype, or
histological variant [4], tumor growth pattern [5], lym-
phovascular invasion [6], and association with in situ
carcinoma [7] also play a central part in orienting
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towards the most appropriate clinical management of
patients.
Despite the lively debate and active research on this
topic, whether or not to opt for radical cystectomy is
sometimes still a dilemma, since it is unclear which pa-
tients might suffer an adverse outcome. Further prog-
nostic morphophenotypic information is much needed.
Although the substaging of the T1 tumors is neither rec-
ommended by the WHO/ISUP, nor included in the VII
edition of the TNM [8], one of the pathological details
most often requested by clinicians is “some form of esti-
mate of lamina propria invasion in pT1 tumors”, as
recently mentioned in Mahul Amin et al. [9]. Many dif-
ferent systems have consequently been proposed in the
literature in the past few years, but none have been
wholly satisfactory. Defining cutoffs for pT1 substaging
has proved challenging. The most widely applied are
histopathological parameters based on invasion of the
muscularis mucosae - i.e. within the lamina propria above
the muscularis mucosae (T1a), within the muscularis
mucosae (T1b), and beyond the muscularis mucosae (T1c)
[10]; or, more simply, above or into vs beyond the muscu-
laris mucosae (T1 a/b) [11]. The main weakness of this
anatomy-based system lies in that it suffers from a lim-
ited feasibility of application and a poor reproducibility.
Another way to distinguish between pT1 tumors is to
measure the maximum extent of invasion at any direc-
tion [12]. Using a size-based approach, van Rhijn et al.
[13] established a clinically significant threshold of in-
vasion at 1 high-power field (HPF 40x) and divided
their cohort of T1 invasive bladder tumors into pT1m
(microinvasive) and pT1e (extensively invasive). The
same approach and substaging threshold were adopted
by Bertz et al. [14]. The aim of the present study is to
test in TUR plus early reTUR specimens a system
(called ROL, from Rete Oncologica Lombarda) based on
a different threshold of microscopically identifiable in-
vasion in a larger group of patients than in the study
conducted by van Rhijn et al., assessing the feasibility
and clinical relevance of this substaging approach as an
oncological outcome predictor, and to compare the
ROL with the anatomy-based T1a/b and the HPF-based
T1m/e substaging methods.
Methods
Five pathologists (CP, LF, MF, PGC, MC) from four differ-
ent high-volume urology referral centers retrospectively
examined multiple slides of a total of 450 transurethral
resections of the bladder (TURB) from patients with an
original diagnosis of T1 high-grade papillary urothelial
carcinoma (tumors graded according to the WHO 2004
Classification). The study was performed in accordance
with the code of conduct of the medical scientific societies
and based on approval of institutional review boards. This
sample was selected from among 502 such cases, 52 of
which were not included in the study because they were
staged as T2 on early reTUR (i.e. the second resection
of the tumor bed performed soon after TURB to ensure
that muscularis propria was obtained). The cases were
gathered from consecutive patients undergoing TURB,
retracing the files from 2011 to 2007, at the Urology
Departments of the St Anna Hospital (Como), San
Raffaele Hospital (Milano), Humanitas Research Hos-
pital (Rozzano, Milano) and National Cancer Institute
(Milano), Italy.
Of the 450 cases considered, 314 (69 %) were con-
firmed as T1 high-grade urothelial carcinomas, while
136 (31 %) were excluded from the study due to errone-
ous grading, revised staging (cases downstaged to Ta or
upstaged to T2), or, more often, because patients were
lost to follow-up. Other histotypes (small cell or adeno-
carcinoma, or squamous cell carcinoma) were also
ruled out. The microscopic criteria used to define inva-
sion were as established in the literature [15], and the
substaging rules adopted were discussed and approved
by all co-authors. In particular, a cutoff of 1 mm of in-
vasion was adopted (we called this substaging approach
ROL [Rete Oncologica Lombarda], after Lombardy On-
cology Network) because the 0.5 mm threshold clinic-
ally tested in another study (van Rhijn et al.; 13) was
too superficial in the opinion of the present authors,
partly because of the uneven thickness of the lamina
propria, which can reach as much as 3 mm in the cu-
pola [16]. Our ROL substaging was thus defined as fol-
lows: ROL1 < 1 PF (objective 20x, ocular 10x/field 22,
diameter 1.1 mm) of invasion, approximately corre-
sponding to invasion of the lamina propria 1 mm thick
or less; ROL2: > 1 PF (objective 20x), approximately
corresponding to invasion of the lamina propria more
than 1 mm thick, or multifocal invasion with foci cu-
mulatively amounting to invasion of the lamina propria
more than 1 mm thick. We measured the major diam-
eter of invasion, or extent of invasion in any direction.
Cases were also anatomically defined as T1a/T1b
(above or into vs below the muscularis mucosae) [11].
In the absence of the muscularis mucosae, the edge of
the invasive tumor was compared with the vascular
plexus of the lamina propria. The van Rhijn substaging
method was applied too [13], i.e. < 1 HPF (objective
40x, ocular 10x/field 22, diameter of 0.55 mm) of lam-
ina propria invasion, approximately corresponding to
0.5 mm of invasion of the lamina propria or less (called
T1m) versus > 1 HPF (objective 40x), approximately
corresponding to more than 0.5 mm of invasion of the
lamina propria, or multifocal invasion without combin-
ing the thickness of individual foci (called T1e). Any
presence of carcinoma in situ (CIS) or neoplastic vascu-
lar invasion was also recorded.
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To test the reproducibility of the substaging systems, a
set of the first 50 consecutive cases was blindly reviewed
by all the pathologists and, in the event of differences of
opinion - 2/50 (4 %) for the ROL, and 1/50 (2 %) for the
T1m/e substaging - cases were discussed to reach a
consensus.
Of the 314 patients considered, 250 (79 %) underwent
repeat TURB (reTUR) within three months of their first
TURB: 141 (56 %) were T0 patients, 40 (16 %) were Ta,
57 (22 %) were T1, 10 (4 %) were CIS, and 2 (0.8 %)
were case of flat dysplasia. Patients diagnosed as T1 at
reTUR were also reviewed by all the pathologists using
the same substaging thresholds, and the residual foci of
infiltration were added to those of the original TUR to
obtain a complete evaluation for substaging purposes.
Clinical follow-up data were collected on all patients,
including disease recurrences and progression. The me-
dian follow-up was 46 months. All patients except those
who underwent cystectomy immediately were treated
with BCG.
Recurrence was defined as a tumor recurring with a
lower or the same stage as the primary tumor, and pro-
gression as a tumor recurring with a higher stage or
metastatic disease. The three substaging methods were
compared in terms of feasibility and prognostic reliabil-
ity. Progression-free survival (PFS) and recurrence-free
survival (RFS) were analyzed by means of Kaplan Meier
estimates. Univariate Cox’s regression analyses were used
to test the risk factors associated with a detrimental ef-
fect on survival.
Statistical analyses
Descriptive statistics of categorical variables focused on
frequencies and proportions. Means, medians and inter-
quartile ranges (IQR) are given for continuously coded
variables. Univariate Cox’s proportional hazard models
were constructed to identify significant predictors of re-
currence and progression after TURB. Kaplan Meier
analyses were plotted to compare different substaging
methods, analyzing recurrence and progression. All ana-
lyses were performed using SPSS v. 20.0 (IBM Corp.,
Armonk, NY, USA).
Results
Our study concerned 314 cases treated with TURB and
confirmed as T1 high-grade urothelial carcinoma ac-
cording to the WHO 2004 Classification, with a mean
follow-up of 46 months. Patients were a mean 71.3 years
of age (range 64–79), and 39 patients (12.4 %) were fe-
male (see Table 1 for the descriptive characteristics). The
reTUR performed in 250 cases was positive in 107: 40
(16 %) were Ta, 57 (22 %) were T1, and 10 (4 %) were
CIS. As mentioned earlier, we considered reTUR within
3 month as a completion of the original procedure for
tumor staging purposes. Hence, residual T1 areas of
infiltration of 57 cases were submitted to the same
analysis reaching a final substaging. All patients were
Table 1 Descriptive characteristics of 314 patients treated with
transurethral resection for T1HG Bladder carcinoma between
2011 and 2007
Variables Overall population
(n = 314, 100 %)
Number recurrence 115 (36.6 %)
Number progression 33 (10.5 %)
Gender
Male 275 (87.6 %)
Female 39 (12.4 %)
Age
Mean 71.3
Median (IQR) 72 (64–79)
Recurrence (EAU classification)
First episode 218 (69.4 %)
Recurrent episode 90 (28.7 %)
More than 1 episode 6 (1.9 %)
Focality
1 140 (44.6 %)
2 24 (7.6 %)
3 66 (21.0 %)
No data 84 (26.8 %)
Pure transitional 281 (89.5 %)
Areas of divergent differentiation 33 (10.5 %)
CIS 54 (17.2 %)
LVI 33 (10.5 %)
SUB-STAGING
MM level feasibility 230 (73.2 %)
van Rhijn system feasibility 314 (100 %)
ROL system feasibility 314 (100 %)
Muscolaris Mucosae
Above (T1a) 177 (56.4 %)
Below (T1b) 51 (16.2 %)
van Rhijn
T1m 109 (34.7 %)
T1e 205 (65.3 %)
ROL
1 152 (48.4 %)
2 162 (51.6 %)
ROL FOCI
2/3 31 (9.9 %)
> 3 99 (31.5 %)
IQR interquartile range, CIS carcinoma in situ, LVI lymphovascular invasion, MM
muscolaris mucosa, ROL rete oncologica lombardia
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treated with BCG, except for those who underwent cyst-
ectomy immediately (52 patients, 16 %).
In the original cohort of 314 patients, there were 90
cases of multifocal disease. CIS was identified in 54 cases
(17.1 %), and vascular invasion in 33 (10.5 %). A papil-
lary urothelial carcinoma histology was seen in 89.5 % of
cases, and the focal variant in the other 11.5 % (33 cases
showing focal adenocarcinoma or squamous cell carcin-
oma differentiation) (Table 1).
As for the feasibility of substaging, the ROL system
was feasible in 100 % of cases, the anatomy-based
method (T1 a/b) in 72.3 %, and the van Rhijn system in
100 %. Figures 1, 2 and 3 show examples of histological
applications of the ROL system compared with van
Rhijn and T1a/b substaging. All the infiltrative patterns
described in the literature were present, i.e. those char-
acterized by a paradoxical differentiation of individual
clusters or single cells, irregular infiltrative tongues and
irregular small or large nests of infiltrative tumor with
fibroinflammatory reactions. Cases revealing ambiguous
or deceptive patterns of infiltration were excluded from
the study and classified as Ta, as recommended in the
literature [17].
After a mean follow-up of 46 months, 115 patients
(36.6 %) had experienced a recurrence, and 33 (10.5 %) a
progression. The recurrence-free survival rate was sig-
nificantly better (p < 0.001) in the group that underwent
reTUR (Fig. 4).
The overall recurrence-free rates (RFR) are shown in
Fig. 5. They were: 53 and 61 % for ROL1 and ROL2, re-
spectively; 55 and 53 % for T1a and T1b, respectively;
and 50 and 61 % for van Rhijn T1m and T1e, respect-
ively. The overall progression-free rates (PFR) are given
in Fig. 6. They were: 92 and 81 % for ROL1 and ROL2,
respectively (p < 0.04); 89 and 78 % for T1a and T1b, re-
spectively; and 91 and 84 % for van Rhijn T1m and T1e,
respectively. Figure 7 shows the PFR for the 64/314 pa-
tients who had no reTUR, and Fig. 8 shows the PFR for
the 250/314 who underwent reTUR; a statistically sig-
nificant difference (p < 0.03) emerged between ROL1
and ROL2.
The results of univariate Cox’s regression analysis
(including CIS and vascular neoplastic invasion) are
given in Table 2: the correlations between the mixed
transitional histology and a lower recurrence rate, and
between ROL substaging and progression reached stat-
istical significance.
Discussion
Accurately staging bladder carcinoma is extremely import-
ant for prognostic purposes and treatment decision-making.
The conclusion reached by the largest meta-analysis ever
Fig. 1 Lamina propria invasion in a high-grade papillary urothelial
carcinoma: T1m/ROL1 substaging (T1 < 0.5 mm)
Fig. 2 Lamina propria invasion in a high-grade papillary urothelial
carcinoma: T1e/ROL1 substaging (the focus is contained within
one x 200 field, although it is larger than one x400 field)
Fig. 3 Multiple foci of lamina propria invasion in a high-grade papillary
urothelial carcinoma: T1e/ROL2 substaging (multifocality of invasion
cumulatively amounting to more than 1 mm, i.e. > 200x field)
Patriarca et al. Diagnostic Pathology  (2016) 11:6 Page 4 of 9
conducted on prognostic factors in high-grade T1 blad-
der carcinoma, recently published by W. Martin-Doyle
et al. in the Journal of Clinical Oncology, was that depth
of invasion is the prognostic factor with the greatest
impact (HR: 3.55) and should be considered for inclu-
sion among the TNM staging criteria [18]. Awareness
of its potential clinical relevance and the ongoing lively
debate on this issue convinced us to undertake the
present study on 314 cases of T1 high-grade urothelial
bladder carcinoma.
The first point worth emphasizing is the greater feasi-
bility of the ROL and van Rhijn substaging approaches
vis-à-vis T1a/b substaging: virtually all cases could be
substaged using the former. This raises the question of
why these systems do not suffer from the shortcomings
of the T1a/b approach. The answer is probably that both
the fragmentation and the modest orientability of TURB
material often precludes any perpendicular definition of
invasive growth and consequent anatomy-based T1a/b
substaging. In addition, the muscularis mucosae and the
vascular plexus that might be considered in lieu of it
[16], are sometimes both absent.
We adopted a HPF-based approach of 20x objective to
measure depth of invasion, which identified 152 cases
(47.8 %) of minimally/initially invasive tumors (ROL1),
i.e. fewer cases than those identified with the deeper T1a
anatomy-based threshold (177 cases) and more than the
number obtained with the shallower threshold proposed
Fig. 4 Recurrence-free survival was significantly better (p < 0.001) in the group that underwent reTUR
Fig. 5 No significant correlations between the three substaging systems and the recurrence-free rate on Kaplan Meier estimates
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by van Rhijn as T1m (109 cases, 34 %). Our choice of a
threshold at 1 mm of invasion was based on three
points: a) a more balanced numerical distribution be-
tween the two subgroups; b) concern that the depth
adopted by van Rhijn was too shallow, given the uneven
thickness of the lamina propria, which reaches up to
3 mm in the cupola [16]; and c) concern that the
anatomy-based T1a/b substaging might be too deep
(we were able to split T1a cases into two groups:
ROL1/T1a: 152 cases and ROL2/T1a: 25 cases).
Histological predictors of progression in high-grade
tumors would be highly desirable, and the thresholds
adopted by van Rhijn et al. [13] in their study proved to
be the only significant independent predictors of pro-
gression and disease-specific survival on multivariate
analysis.
When compared with the other substaging systems,
our ROL approach seemed a promising threshold for
predicting progression, much more feasible than the
T1a/b system, and the only cutoff proving statistically
significant on Kaplan Meier estimates (p < 0.04) (Fig. 6).
The correlation between ROL substaging and progression
reached statistical significance on univariate Cox’s regres-
sion analysis (Table 2).
Not surprisingly, none of the three substaging systems
reliably predicted recurrence (p > 0.05), probably because
of the important role of reTUR (Fig. 5). Although multi-
focality is a common finding in bladder cancer, and both
low-grade and high-grade carcinomas may recur, these
recurrences are usually local - as in our sample, where
the recurrence-free survival rate was significantly better
(p < 0.001) in the group that underwent reTUR (Fig. 4).
The contribution of reTUR to final substaging is sig-
nificant in terms of PFR too. None of the three
methods were able to predict progression in the group
of 64 who had no reTUR (Fig. 7), whereas the ROL
again reached statistical significance in the Kaplan
Meier estimates (p < 0.03) in the group of 250 patients
who underwent reTUR (Fig. 8).
Several studies have addressed the issue of bladder
cancer substaging in the past [10, 11, 19]. The study
published by Cheng [19], one of the most often quoted
in the subsequent literature, defines a depth of invasion
of 1.5 mm as clinically relevant. Given the previously-
Fig. 6 Progression-free rate: ROL substaging shows a significant correlation with progression in the Kaplan Meier estimates
Fig. 7 None of the three methods were able to predict progression in the group of 64 cases not treated with reTUR
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mentioned uneven thickness of the lamina propria [16],
this threshold is probably too deep, particularly in the
trigone. Some whole-tumor chips of TUR material may
contain detrusor muscle fibers that are not easy to de-
tect without special immunostains like smoothelin [20].
Many studies might consequently include a variable pro-
portion of understaged pT2 cases [18].
The anatomical approaches adopted by other authors
[10, 11] suffer from the above-mentioned shortcomings,
so the studies conducted by Bertz [14], Chang [12] and
van Rhijn [13] represent a significant step forward, hav-
ing ratified a quantitative microscopic assessment and
also a shallower depth of invasion than the 1.5 mm
threshold.
In the Chang et al. study [12], for instance, patients
with high-grade carcinoma invading > 1 mm had a sig-
nificantly worse outcome in terms of progression. These
authors adopted the criterion of combining the sizes of
individual foci of invasion, as in the present study, but
they did not consider any early reTUR, which guarantees
a complete substaging. In the study by van Rhijn et al.
[13], on the other hand, the number of patients under-
going early reTUR is not stated and any cases of residual
T1 were apparently not submitted to the same substa-
ging procedure.
Concerning the limited prognostic relevance of any
carcinoma in situ (CIS) in our study, it should be
stressed that the diagnosis of CIS could be based on its
detection in the peritumoral area, at the base of the pa-
pillae, or in any suspicious flat areas identified on cold
biopsy. Such different approaches might lead to true
CIS going underdetected, “diluting any observed effect of
reported CIS toward the null” [18]. A better standardization
of its definition could help unravel the question of its rele-
vance. The weak prognostic value of lymphovascular inva-
sion (LVI) in our study could be influenced by its relatively
low incidence (10 % in our sample). Also in the study of F.
Brimo et al. [21] about the value of millimetric invasion in
T1 bladder carcinoma, LVI and concomitant CIS were
less important than T1 depth of invasion (recorded by
the Authors only in properly oriented specimens).
Our study has some limitations. First of all, patients’
data were retrieved retrospectively from our database,
so our results may potentially be affected by all the lim-
itations deriving from a retrospective design, including
the fact that not all patients (79 %, 250/314) underwent
Fig. 8 Progression-free rate: ROL substaging shows a significant correlation with progression in the Kaplan Meier estimates for the 250 cases
treated with reTUR
Table 2 Univariate Cox regression analyses assessing recurrence and progression after transuretral resection due to T1HG bladder cancer
Variables Univariate Recurrence Univariate Progression
HR (IQR) P value HR (IQR) P value
Age, years 0.99 (0.98–1.01) 0.5 1.00 (0.97–1.04) 0.8
ROL 2 vs ROL 1 0.81 (0.56–1.18) 0.2 2.09 (1.01–4.32) 0.04
T1e vs T1m 0.77 (0.53–1.11) 0.1 1.68 (0.78–3.63) 0.2
T1b vs T1a 1.25 (0.78–2.01) 0.4 2.06 (0.91–4.67) 0.08
CIS 0.77 (0.66–1.75) 0.7 1.44 (0.62–3.37) 0.4
LVI 1.11 (0.62–1.98) 0.7 2.55 (1.10–5.89) 0.03
Pure Transtitional vs. non pure transitional 0.40 (0.16.0.97) 0.04 0.31 (0.04–2.29) 0.2
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reTUR. Second, no multivariate models were included
in our analysis: this was a consequence of our limited
cohort. Third, few progressions were recorded and this
reduces the power of the study. Our progression rate
was lower than in historical series published in the lit-
erature and this might be explained by the grade migra-
tion induced by the WHO 2004 Classification, and by
the fact that 79 % of our patients underwent reTUR. Fi-
nally, the time frame between the first and second
TURB procedures was as long as 3 months, and the
total number of BCG instillations per patient was not
taken into account.
As a final comment, it has been claimed that en bloc
resection can overcome the drawbacks of conventional
TURB [22]. Although tumor size and site might some-
times make en bloc resection difficult, removing the
whole lesion would offer the following advantages: eas-
ier T1 substaging thanks to the specimen’s orientability;
definition of the margins of resection (marked with
ink), providing an indication of microscopic distance;
significantly reduced seeding phenomena and a conse-
quent reduction of early recurrences [23] and reTUR
procedures. After all, from a surgical pathologist’s point
of view, it is a matter of affording papillary urothelial
carcinoma of the bladder the same dignity as other
small surgical specimens, such as intestinal polyps or
cervical conizations.
Conclusion
In conclusion, although the international uropathology
community [9] suggests that pT1 substaging would
provide information important to clinicians, the histo-
logical approach has yet to be standardized. We believe,
however, that a pure quantitative assessment of the ex-
tent of tumor invasion is promising and “user-friendly”
and that 1 mm of invasion might represent a clinically
useful threshold.
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